文献速递肝肾功能剂量调整药物相互作用抗栓抗凝管理

华法林-胺碘酮药物相互作用幅度随肾功能变化:倾向匹配队列研究

The Magnitude of the Warfarin-Amiodarone Drug-Drug Interaction Varies With Renal Function: A Propensity-Matched Cohort Study.
PubMed 文献 · Clin Pharmacol Ther · 2020-03-26

该倾向匹配队列研究纳入住院房颤患者,比较胺碘酮组与对照组,发现胺碘酮对华法林反应的影响随肾功能下降而减弱:正常肾功能时WSI增加36%,严重肾功能不全时仅增加11.8%;对INR>4风险的影响同样随肾功能下降而减弱。

要点

  • 胺碘酮对华法林反应的影响随肾功能下降而减弱,正常肾功能时WSI增加36%,严重肾功能不全时仅增加11.8%。
  • 胺碘酮在正常肾功能患者中显著增加INR>4风险(HR 1.80),但在严重肾功能不全患者中影响可忽略(HR 1.01)。
  • 肾功能是解释华法林-胺碘酮相互作用个体间变异的新因素。

核心结论

  • 肾功能是解释华法林-胺碘酮药物相互作用幅度个体间变异的新因素。

研究设计与样本

  • 倾向匹配队列研究,纳入住院房颤患者,胺碘酮组和对照组各4,518例。
  • 肾功能以肌酐清除率(CrCl)评估,华法林反应以华法林敏感指数(WSI)衡量,采用多水平混合效应线性回归和Cox回归建模。

主要发现

  • 胺碘酮对华法林反应的影响在肾功能范围内变化达三倍:正常肾功能(CrCl 115 mL/min)时WSI增加36%,严重肾功能不全(CrCl 15 mL/min)时仅增加11.8%。

临床怎么用

  • 肾功能可指导华法林剂量调整和监测,并可能影响接受胺碘酮治疗患者的口服抗凝药选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Amiodarone inhibits warfarin metabolism and is associated with major bleeding during warfarin therapy. Managing this drug-drug interaction (DDI) is challenging because of substantial interpatient variability in DDI magnitude. Because renal dysfunction induces changes in drug metabolism and protein binding that could alter cytochrome P450 inhibition mechanisms, we hypothesized that renal dysfunction alters the impact of the warfarin-amiodarone DDI. We tested this question in a propensity-matched cohort study of hospitalized patients with atrial fibrillation. Patients were queried from an electronic health record database. Renal function was estimated with creatinine clearance (CrCl). Warfarin response was measured with the warfarin sensitivity index (WSI), a dose-normalized international normalized ratio (INR) measure, and was modeled with multilevel mixed-effects linear regression. Time to supratherapeutic INR (> 4) was modeled using Cox regression. Propensity score matching resulted in 4,518 patients administered amiodarone and 4,518 controls. Amiodarone's effect on warfarin response varied threefold across the renal function range, increasing WSI by 36% in patients with normal renal function (CrCl 115 mL/minute), but by only 11.8% in patients with severe renal dysfunction (CrCl 15 mL/minute). Similarly, amiodarone had a strong effect in patients with normal renal function (hazard ratio (HR) 1.80; 1.23, 2.64), but a negligible effect on supratherapeutic INR hazard in patients with severe renal dysfunction (HR 1.01; 0.75, 1.37). These results suggest that renal function is a novel factor that explains substantial variability in the warfarin-amiodarone DDI. This information could inform warfarin dosage adjustment and monitoring and may have implications for the selection of oral anticoagulation agents in patients treated with amiodarone.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Miano TA, Yang W, Shashaty MGS, et al. The Magnitude of the Warfarin-Amiodarone Drug-Drug Interaction Varies With Renal Function: A Propensity-Matched Cohort Study. Clin Pharmacol Ther. 2020. PMID: 32112562. doi:10.1002/cpt.1819

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。